全基因组测序用于胚胎植入前综合遗传学检测的评估
该研究纳入10个家庭共53枚胚胎(24枚卵裂球和29枚囊胚),评估全基因组测序(WGS)用于胚胎植入前单基因病检测(PGT-M)、非整倍体检测(PGT-A)和结构重排检测(PGT-SR)的可行性。结果显示,在父母10×和胚胎4×测序深度下,WGS与SNP阵列及MicroSeq结果均100%一致,且无需额外家庭成员即可进行单倍型分析。
要点
- WGS可在父母10×、胚胎4×深度下实现可靠的基因组单倍型分析和综合PGT。
- WGS与SNP阵列用于PGT-M和PGT-A的胚胎结果100%一致。
- WGS可检测胚胎平衡易位,与MicroSeq结果100%一致,且无需额外家庭成员。
核心结论
- WGS-based PGT-A、PGT-M和PGT-SR提供了一种无需额外家庭成员的综合PGT单倍型分析方案。
- WGS可作为低深度MPS和SNP阵列等PGT方法的有益补充。
研究设计与样本
- 研究纳入10个曾接受传统IVF-PGT的家庭和53枚胚胎,包括2个PGT-SR家庭的13枚胚胎和8个PGT-M家庭的40枚胚胎。
- 胚胎样本共24枚卵裂球和29枚囊胚,所有胚胎均用于PGT-A,并以核型定位(Karyomapping)验证WGS结果。
主要发现
- 对于40枚PGT-M和53枚PGT-A胚胎,无论是否包含额外家庭成员或先证者进行单倍型分析,WGS与SNP阵列结果均100%一致。
- 对于2个PGT-SR家庭的13枚胚胎,WGS检测到胚胎平衡易位,与MicroSeq结合PCR测序结果100%一致。
关键数值与推荐
- 可靠的全基因组单倍型分析、PGT-M、PGT-A和PGT-SR可在父母10×和胚胎4×测序深度下完成。
- WGS与SNP阵列用于PGT-M和PGT-A的胚胎结果一致率为100%。
- WGS与MicroSeq用于PGT-SR的胚胎结果一致率为100%。
临床怎么用
- 对于需要进行PGT-M或PGT-SR单倍型分析但缺乏额外家庭成员或先证者的家庭,可考虑采用WGS-based方法。
- WGS可同时进行PGT-A、PGT-M和PGT-SR,提供综合检测方案。
局限性
- 本研究样本量有限。
- 部分病例因直接基因分型失败而无法获得用于PGT-M或PGT-SR父母仅单倍型分析的参考胚胎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can whole genome sequencing (WGS) offer a relatively cost-effective approach for embryonic genome-wide haplotyping and preimplantation genetic testing (PGT) for monogenic disorders (PGT-M), aneuploidy (PGT-A) and structural rearrangements (PGT-SR)? SUMMARY ANSWER: Reliable genome-wide haplotyping, PGT-M, PGT-A and PGT-SR could be performed by WGS with 10× depth of parental and 4× depth of embryonic sequencing data. WHAT IS KNOWN ALREADY: Reduced representation genome sequencing with a genome-wide next-generation sequencing haplarithmisis-based solution has been verified as a generic approach for automated haplotyping and comprehensive PGT. Several low-depth massively parallel sequencing (MPS)-based methods for haplotyping and comprehensive PGT have been developed. However, an additional family member, such as a sibling, or a proband, is required for PGT-M haplotyping using low-depth MPS methods. STUDY DESIGN, SIZE, DURATION: In this study, 10 families that had undergone traditional IVF-PGT and 53 embryos, including 13 embryos from two PGT-SR families and 40 embryos from eight PGT-M families, were included to evaluate a WGS-based method. There were 24 blastomeres and 29 blastocysts in total. All embryos were used for PGT-A. Karyomapping validated the WGS results. Clinical outcomes of the 10 families were evaluated. PARTICIPANTS/MATERIALS, SETTING, METHODS: A blastomere or a few trophectoderm cells from the blastocyst were biopsied, and multiple displacement amplification (MDA) was performed. MDA DNA and bulk DNA of family members were used for library construction. Libraries were sequenced, and data analysis, including haplotype inheritance deduction for PGT-M and PGT-SR and read-count analysis for PGT-A, was performed using an in-house pipeline. Haplotyping with a proband and parent-only haplotyping without additional family members were performed to assess the WGS methodology. Concordance analysis between the WGS results and traditional PGT methods was performed. MAIN RESULTS AND THE ROLE OF CHANCE: For the 40 PGT-M and 53 PGT-A embryos, 100% concordance between the WGS and single-nucleotide polymorphism (SNP)-array results was observed, regardless of whether additional family members or a proband was included for PGT-M haplotyping. For the 13 embryos from the two PGT-SR families, the embryonic balanced translocation was detected and 100% concordance between WGS and MicroSeq with PCR-seq was demonstrated. LIMITATIONS, REASONS FOR CAUTION: The number of samples in this study was limited. In some cases, the reference embryo for PGT-M or PGT-SR parent-only haplotyping was not available owing to failed direct genotyping. WIDER IMPLICATIONS OF THE FINDINGS: WGS-based PGT-A, PGT-M and PGT-SR offered a comprehensive PGT approach for haplotyping without the requirement for additional family members. It provided an improved complementary method to PGT methodologies, such as low-depth MPS- and SNP array-based methods. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by the research grant from the National Key R&D Program of China (2018YFC0910201 and 2018YFC1004900), the Guangdong province science and technology project of China (2019B020226001), the Shenzhen Birth Defect Screening Project Lab (JZF No. [2016] 750) and the Shenzhen Municipal Government of China (JCYJ20170412152854656). This work was also supported by the National Natural Science Foundation of China (81771638, 81901495 and 81971344), the National Key R&D Program of China (2018YFC1004901 and 2016YFC0905103), the Shanghai Sailing Program (18YF1424800), the Shanghai Municipal Commission of Science and Technology Program (15411964000) and the Shanghai 'Rising Stars of Medical Talent' Youth Development Program Clinical Laboratory Practitioners Program (201972). The authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Chen S, Yin X, Zhang S, et al. Comprehensive preimplantation genetic testing by massively parallel sequencing. Hum Reprod. 2021. PMID: 33306794. doi:10.1093/humrep/deaa269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。